Xagrid is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets in the blood). ‘Essential’ means that the disease has no obvious cause.
Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are ‘at risk’ because of their age (over 60 years), very high platelet counts or previous clotting problems.
Xagrid contains the active substance anagrelide.
Xagrid : EPAR - Medicine overview (PDF/74.48 KB)
First published: 20/11/2009
Last updated: 02/08/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Shire Pharmaceuticals Ireland Limited
|Date of issue of marketing authorisation valid throughout the European Union||
30/01/2020 Xagrid - EMEA/H/C/000480 - II/0086
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
An at-risk patient
An at-risk ET is defined by one or more of the following features:
- >60 years of age or;
- a platelet count >1000 x 109/l or;
- a history of thrombohaemorrhagic events.